All News
Enthesitis Responses to Secukinumab in Spondylitis Patients
Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.
Read Article
Rheumatic Patients Are at Risk for COVID Death
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Low Anaphylaxis Risk with COVID mRNA Vaccines
JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals.
Read Article
COVID-19-Related Deaths in Rheumatic Disease Patients
There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.
Read Article
Comparison of Three Coronavirus Vaccines
On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available. We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Low IBD Risk with IL-17 Inhibition
Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.
Read Article
Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul
Read Article
RheumNow Podcast – Pounds of Prevention (3.5.2021)
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
Baricitinib Therapy in Covid-19 Pneumonia
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Paucity of Effectiveness Research on Telemedicine in RA
A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences.
Read Article
Combo Therapy Boosts Response in Uncontrolled Gout
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19
The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.
Read Article
MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.
Read Article